Clinical trials of FcRn inhibitors, such as efgartigimod and rozanolixizumab, have demonstrated comparable reductions in pathogenic IgG levels to those achieved with PLEX in diseases like myasthenia gravis and immune thrombocytopenia, with fewer procedure-related risks and greater patient convenience [80,83,85]. Here, FCGRT is linked to autoimmune thrombocytopenic purpura.